片仔癀(600436.SH)：PZH2113胶囊Ⅰ期临床试验完成首例受试者入组

Core Viewpoint - The company Pianzaihuang (600436.SH) has initiated a Phase I clinical trial for the PZH2113 capsule, targeting relapsed/refractory B-cell non-Hodgkin lymphoma, primarily diffuse large B-cell lymphoma, with the first subject enrolled in the study [1]. Group 1 - The clinical trial is an open-label, multi-center, Phase I study focusing on the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of the PZH2113 capsule [1]. - The specific indication for this trial is relapsed/refractory non-Hodgkin lymphoma, with a primary focus on diffuse large B-cell lymphoma [1].